Published in Ann Intern Med on October 01, 1969
Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest (1975) 1.88
Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest (1982) 1.45
Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med (1970) 1.38
Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest (1975) 1.16
Human skin proteases: separation and characterization of two alkaline proteases, one splitting trypsin and the other chymotrypsin substrates. Arch Dermatol Res (1975) 1.10
Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. J Clin Invest (1977) 1.01
Effect of antimicrobial therapy on lung bacterial clearance in the burned rat. Ann Surg (1972) 1.01
Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest (1978) 0.94
Immunochemical studies of plasma kallikrein. J Clin Invest (1974) 0.94
Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest (1980) 0.94
Hyperacute renal allograft rejection in the primate. Therapeutic limitations of antiplatelet agents alone and combined with heparin. Am J Pathol (1976) 0.86
Studies of the kallikrein-kinin system in patients with sickle cell anemia. J Natl Med Assoc (1983) 0.80
Studies on the prekallikrein-bradykininogen system in liver disease. J Clin Pathol (1972) 0.80
Studies of contact activation of blood in haemodialysis. J Clin Pathol (1972) 0.75
An enzyme in pigeon droppings, of possible relevance to pigeon breeder's disease. Clin Exp Immunol (1972) 0.75
A study of the effect of acute systemic anaphylaxis on blood coagulation and TAME esterase activity in calves. Can J Comp Med (1980) 0.75
Alterations in responses to bradykinin, angiotensin I, and angiotensin II during the induction phase of one-kidney, one-wrapped hypertension and associated arterial disease in rabbits. Am J Pathol (1980) 0.75
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS. J Clin Invest (1949) 8.50
Thrombolytic therapy: current status (1). N Engl J Med (1988) 5.44
Acrasin, Acrasinase, and the sensitivity to acrasin in Dictyostelium discoideum. Dev Biol (1969) 3.56
Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep (1978) 2.63
THE VITAMIN C REQUIREMENT OF MAN. ESTIMATED AFTER PROLONGED STUDIES OF THE PLASMA CONCENTRATION AND DAILY EXCRETION OF VITAMIN C IN 3 ADULTS ON CONTROLLED DIETS. J Clin Invest (1939) 2.43
Low urinary cortisol excretion in Holocaust survivors with posttraumatic stress disorder. Am J Psychiatry (1995) 2.39
Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost (1991) 2.29
Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation (1983) 2.24
Platelet function in hyperlipoproteinemia. N Engl J Med (1974) 2.23
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation. Dig Liver Dis (2005) 2.18
Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med (1983) 2.18
Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol (1980) 2.17
Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg (1996) 2.11
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Amiodarone. N Engl J Med (1987) 2.05
Advances in the understanding of myocarditis. Circulation (2001) 1.93
Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest (1975) 1.88
Disseminated intravascular coagulation (DIC): an approach. Am J Med (1972) 1.87
Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation (1996) 1.86
Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation (1997) 1.84
Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med (1983) 1.81
Deficits in short-term memory in posttraumatic stress disorder. Am J Psychiatry (1993) 1.81
Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A (1976) 1.69
Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep (1978) 1.68
Techniques for right and left ventricular endomyocardial biopsy. Am J Cardiol (1978) 1.68
A review of psychoendocrine research on the pituitary-adrenal cortical system. Psychosom Med (1969) 1.65
Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med (1992) 1.65
Early anthracycline cardiotoxicity. Am J Med (1978) 1.63
Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis (1990) 1.63
Coagulation studies in the hyperacute and other forms of renal-allograft rejection. N Engl J Med (1969) 1.62
Purification and characterization of a potent 70-kDa thiol lysyl-proteinase (Lys-gingivain) from Porphyromonas gingivalis that cleaves kininogens and fibrinogen. J Biol Chem (1993) 1.61
Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry (1993) 1.56
Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest (1975) 1.55
Plasma kallikrein and Hageman factor in Gram-negative bacteremia. Ann Intern Med (1970) 1.53
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest (1969) 1.52
Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. Biol Psychiatry (1991) 1.52
Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol (1974) 1.51
Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Electrophysiologic Study Versus Electromagnetic Monitoring. Circulation (1997) 1.49
Thrombolytic therapy: current status (2). N Engl J Med (1988) 1.49
Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest (1982) 1.45
Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun (1969) 1.44
Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest (1977) 1.42
Lack of clinically significant contact system activation during platelet concentrate filtration by leukocyte removal filters. Blood (1998) 1.42
Multiple hormonal responses to graded exercise in relation to physical training. J Appl Physiol (1972) 1.42
Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. Am J Med (1971) 1.41
Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry (1981) 1.41
Invited letter concerning: aprotinin. J Thorac Cardiovasc Surg (1991) 1.40
Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest (1984) 1.40
Inhibition of insulin secretion by infused epinephrine in rhesus monkeys. Endocrinology (1966) 1.39
Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood (1986) 1.38
The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest (1993) 1.38
Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest (1984) 1.35
Urinary free-cortisol levels in posttraumatic stress disorder patients. J Nerv Ment Dis (1986) 1.35
Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med (1978) 1.34
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest (1969) 1.34
More on kininogen measurements in platelet concentrates that are white cell (WBC) reduced with WBC-reduction filters. Transfusion (1996) 1.33
Effects of Physicochemical Factors and Bacterial Colony Morphotype on Association of Vibrio vulnificus with Hemocytes of Crassostrea virginica. Appl Environ Microbiol (1993) 1.32
Current status of antithrombotic therapy in cardiovascular disease. Prog Cardiovasc Dis (1977) 1.31
The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry (1966) 1.31
THE MECHANISM OF THE EXCRETION OF VITAMIN C BY THE HUMAN KIDNEY AT LOW AND NORMAL PLASMA LEVELS OF ASCORBIC ACID. J Clin Invest (1940) 1.30
Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol (1965) 1.28
Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation (1978) 1.28
Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J (1981) 1.27
Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am Rev Respir Dis (1985) 1.27
Circulating anticoagulants to factor VIII. Immunochemical studies and clinical response to factor VIII concentrates. Am J Med (1970) 1.26
Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry (1984) 1.25
Multiple hormonal responses to prolonged exercise in relation to physical training. J Appl Physiol (1972) 1.24
Viability of Vibrio vulnificus in Association with Hemocytes of the American Oyster (Crassostrea virginica). Appl Environ Microbiol (1995) 1.23
Origin of the high molecular weight activator of prekallikrein. J Biol Chem (1973) 1.22
Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest (1983) 1.22
Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest (1982) 1.21
Formation of human plasma kinin. N Engl J Med (1974) 1.21
Fibrinolysis. Annu Rev Med (1968) 1.20
3'5' AMP and Ca 2+ in slime mold aggregation. Exp Cell Res (1971) 1.18
Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders. Biol Psychiatry (1993) 1.18
Human plasma prekallikrein: a rapid high-yield method for purification. Eur J Biochem (1979) 1.17
The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem (1985) 1.17
Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. Biochemistry (1967) 1.17
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb (1992) 1.16
Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest (1975) 1.16
A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med (1970) 1.14
Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res (1984) 1.14
Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest (1982) 1.13
Endomyocardial biopsy: the balance of success and failure. Circulation (1985) 1.13
Identification of adenine nucleotide binding proteins in human platelet membranes by affinity labeling with 5'-p-flurosulfonylbenzoyl adenosine. J Biol Chem (1978) 1.11
Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem (1992) 1.11
Amiodarone pulmonary toxicity and Professor Hounsfield. J Cardiovasc Electrophysiol (2001) 1.10
Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep (1978) 1.10
Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol (1977) 1.10
Subcellular localization and secretion of factor V from human platelets. Proc Natl Acad Sci U S A (1981) 1.09
Critical role of the carbohydrate side chains of collagen in platelet aggregation. J Clin Invest (1972) 1.09